Factor VII TRIZ Cases
- Implantable Particles With Modified Shells for Reduced Foreign Body Response
Modified particle shells reduce foreign body response while preserving cell encapsulation.
- Non-AAV ITR Nucleic Acid Vectors for Sustained Therapeutic Expression
Naked nucleic acid molecules use non-AAV ITRs to avoid capsid immunogenicity and support sustained therapeutic expression.
- ECM-Affinity Cytokine Conjugates for Tumor Localization
This case uses collagen-binding ECM-affinity peptides to retain cytokines in tumors, reducing systemic exposure and required dose.
- Therapeutic Exosome Surface Engineering for High-Purity Affinity Purification
Surface markers enable affinity purification and therapeutic peptide localization while reducing exosome heterogeneity.
- Tissue-Specific Promoters for Factor VIII Expression and Immune Rejection
This case uses VEC, KDR, ITGA, and Gp promoters to target Factor VIII expression, improving secretion while limiting antibody formation.